These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 1348430)

  • 1. Plasma homovanillic acid, plasma anti-D1 and -D2 dopamine-receptor activity, and negative symptoms in chronically mediated schizophrenia.
    Suzuki E; Kanba S; Nibuya M; Koshikawa H; Nakaki T; Yagi G
    Biol Psychiatry; 1992 Feb; 31(4):357-64. PubMed ID: 1348430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal changes in symptoms and plasma homovanillic acid levels in chronically medicated schizophrenic patients.
    Suzuki E; Kanba S; Nibuya M; Adachi S; Sekiya U; Shintani F; Kinoshita N; Yagi G; Asai M
    Biol Psychiatry; 1994 Nov; 36(10):654-61. PubMed ID: 7880934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Negative symptoms in nondeficit syndrome respond to neuroleptic treatment with changes in plasma homovanillic acid concentrations.
    Suzuki E; Kanba S; Koshikawa H; Nibuya M; Yagi G; Asai M
    J Psychiatry Neurosci; 1996 May; 21(3):167-71. PubMed ID: 8935328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma homovanillic acid, serum anti-D1 and anti-D2 receptor activity, and psychopathology in chronic schizophrenia.
    Koshikawa H; Suzuki E; Kanba S; Nibuya M; Ishizuki T; Kohno H; Kinoshita N; Shintani F; Yagi G; Nakaki T
    Yakubutsu Seishin Kodo; 1991 Feb; 11(1):79-81. PubMed ID: 1679276
    [No Abstract]   [Full Text] [Related]  

  • 5. Plasma homovanillic acid differences in clinical subgroups of first episode schizophrenic patients.
    Baeza I; Castro-Fornieles J; Deulofeu R; de la Serna E; Goti J; Salvà J; Bernardo M
    Psychiatry Res; 2009 Jul; 168(2):110-8. PubMed ID: 19501918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sex differences in plasma homovanillic acid levels in schizophrenia and normal controls: relation to neuroleptic resistance.
    Sumiyoshi T; Hasegawa M; Jayathilake K; Meltzer HY
    Biol Psychiatry; 1997 Mar; 41(5):560-6. PubMed ID: 9046988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. D1 and D2 and D3.
    Healy D
    Br J Psychiatry; 1991 Sep; 159():319-24. PubMed ID: 1683592
    [No Abstract]   [Full Text] [Related]  

  • 8. B-HT 920, a dopamine D2 agonist, in the treatment of negative symptoms of chronic schizophrenia.
    Ohmori T; Koyama T; Inoue T; Matsubara S; Yamashita I
    Biol Psychiatry; 1993 May; 33(10):687-93. PubMed ID: 8102551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increments in plasma homovanillic acid concentrations after neuroleptic discontinuation are associated with worsening of schizophrenic symptoms.
    Khan RS; Amin F; Powchik P; Knott P; Goldstein M; Apter S; Kerman B; Jaff S; Davidson M
    Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(6):879-84. PubMed ID: 1980541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of aripiprazole and the Taq1A polymorphism in the dopamine D2 receptor gene on the clinical response and plasma monoamine metabolites level during the acute phase of schizophrenia.
    Miura I; Takeuchi S; Katsumi A; Mori A; Kanno K; Yang Q; Mashiko H; Numata Y; Niwa S
    J Clin Psychopharmacol; 2012 Feb; 32(1):106-9. PubMed ID: 22198450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High central D2-dopamine receptor occupancy as assessed with positron emission tomography in medicated but therapy-resistant schizophrenic patients.
    Coppens HJ; Slooff CJ; Paans AM; Wiegman T; Vaalburg W; Korf J
    Biol Psychiatry; 1991 Apr; 29(7):629-34. PubMed ID: 1675892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma homovanillic acid levels in schizophrenic patients: correlation with negative symptoms.
    Dávila R; Zumárraga M; Basterreche N; Arrúe A; Anguiano JB
    Psychiatry Res; 2007 May; 151(1-2):163-8. PubMed ID: 17434602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of schizophrenic symptoms and changes in plasma HVA concentrations, plasma anti-D2 and anti-5-HT2 receptor activities with clozapine.
    Yamada K; Kanba S; Wang ZC; Suzuki E; Fang YY; Yan HG; Nibuya M; Yagi G; Asai M
    Psychiatry Clin Neurosci; 1996 Oct; 50(5):291-4. PubMed ID: 9201793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in plasma homovanillic acid concentrations in schizophrenic patients following neuroleptic discontinuation.
    Davidson M; Kahn RS; Powchik P; Warne P; Losonczy MF; Kaminsky R; Apter S; Jaff S; Davis KL
    Arch Gen Psychiatry; 1991 Jan; 48(1):73-6. PubMed ID: 1670618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma homovanillic acid levels in first-episode schizophrenia. Psychopathology and treatment response.
    Koreen AR; Lieberman J; Alvir J; Mayerhoff D; Loebel A; Chakos M; Amin F; Cooper T
    Arch Gen Psychiatry; 1994 Feb; 51(2):132-8. PubMed ID: 7905259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perspectives on a time-dependent model of neuroleptic action.
    Pickar D
    Schizophr Bull; 1988; 14(2):255-68. PubMed ID: 2904694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma HVA in psychiatric patients: longitudinal studies.
    Javaid JI; Sharma RP; Janicak PG; Davis JM
    Psychopharmacol Bull; 1990; 26(3):361-5. PubMed ID: 2274637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in [3H]-spiperone binding to peripheral blood lymphocytes from neuroleptic responsive and nonresponsive schizophrenic patients.
    Grodzicki J; Pardo M; Schved G; Schlosberg A; Fuchs S; Kanety H
    Biol Psychiatry; 1990 Jun; 27(12):1327-30. PubMed ID: 1973057
    [No Abstract]   [Full Text] [Related]  

  • 19. The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. D4 Dopamine Antagonist Group.
    Kramer MS; Last B; Getson A; Reines SA
    Arch Gen Psychiatry; 1997 Jun; 54(6):567-72. PubMed ID: 9193198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: implications for dopamine D2 receptor occupancy during maintenance treatment in schizophrenia.
    Ikai S; Remington G; Suzuki T; Takeuchi H; Tsuboi T; Den R; Hirano J; Tsunoda K; Nishimoto M; Watanabe K; Mimura M; Mamo D; Uchida H
    J Clin Psychiatry; 2012 Aug; 73(8):1147-52. PubMed ID: 22967779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.